Get started
Author

Tim Strüßmann

Observed names: T. Struessmann, T. Strüßmann, Tim Struessmann, Tim Strüssmann
ORCID: 0000-0002-4975-1599
Observed ORCID: 0000-0002-4975-1599
OpenAlex ID: A5032315126
Platelet-derived MIF: A novel platelet chemokine with distinct recruitment properties
2014 · Theresa H. Wirtz, Sabine Tillmann, et al. · Atherosclerosis · 57
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years
2024 · Philipp Berning, Mathilde Fekom, et al. · Blood Cancer Journal · 33
High Postoperative Blood Levels of Macrophage Migration Inhibitory Factor Are Associated with Less Organ Dysfunction in Patients after Cardiac Surgery
2012 · Christian Stoppe, Gerrit Grieb, et al. · Molecular Medicine · 31
PDF
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
2022 · Tim Strüßmann, Johannes Jung, et al. · Annals of Hematology · 24
PDF
Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?
2024 · Tim Strüßmann, Reinhard Marks, et al. · Cancers · 12
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
2023 · Ralph Wäsch, Tim Strüssmann, et al. · Annals of Hematology · 12
PDF
The impact of pulmonary function in patients undergoing autologous stem cell transplantation
2021 · Jesús Duque-Afonso, Sophie Ewald, et al. · Blood Advances · 12
Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
2020 · Miguel Waterhouse, Sandra Pennisi, et al. · Bone Marrow Transplantation · 12
PDF
Favourable outcomes of poor prognosis diffuse large B‐cell lymphoma patients treated with dose‐dense Rituximab, high‐dose Methotrexate and six cycles of CHOP ‐14 compared to first‐line autologous transplantation
2017 · Tim Strüßmann, Kristina Fritsch, et al. · British Journal of Haematology · 9
Long‐term complete remissions of refractory severe idiopathic immune thrombocytopenia treated with daratumumab: A case series
2024 · T. Strüßmann, J. Heinz, et al. · British Journal of Haematology · 7
Dosage of high‐dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse
2023 · Matthew R. Wilson, Amy A. Kirkwood, et al. · American Journal of Hematology · 6
PDF
Favourable outcomes of double‐hit/double‐expressor lymphoma and high‐grade B‐cell lymphoma, not otherwise specified after early dose‐intensive treatment and up‐front autologous stem cell transplantation: a single‐centre retrospective experience
2022 · Tim Strüßmann, Franziska Glatzki, et al. · British Journal of Haematology · 5
Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
2023 · Anna Katharina Foerster, Corinna Kronenthaler, et al. · Blood · 4
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients
2024 · Tim Strüßmann, Philipp Hermes, et al. · European Journal Of Haematology · 3
PDF
Long-term remissions in refractory ITP patients by daratumumab
2025 · Julian List, Tim Strüßmann, et al. · Blood · 2
PDF
A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin
2022 · T. Strüßmann, R. Wäsch, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2
Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients
2021 · Matthew R Wilson, Toby A. Eyre, et al. · Blood · 2
Dose Intensification with Rituximab, MTX and CHOP Results in Superior Results for Young High Risk DLBCL Patients Than Primary Autologous Transplantation
2015 · Reinhard Marks, Tim Strüssmann, et al. · Blood · 2
O005 Platelet expression of MIF and its secretion by thrombogenic stimulation
2012 · S. Tillmann, T. Strüßmann, et al. · Cytokine · 2
High-Dose Busulfan and Thiotepa Followed by Autologous Stem Cell Transplantation for Refractory Choriocarcinoma with Central Nervous System Metastases: A Case Report
2026 · Julian Rapp, Reinhard Marks, et al. · Case Reports in Oncology · 1
PDF
Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation
2023 · David Alber, Christoph Rummelt, et al. · Blood · 1
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning
2023 · Radu‐Florian Gherman, Sophie Ewald, et al. · European Journal Of Haematology · 1
Pb2126: R-cpop as First Line Treatment for Dlbcl Patients With Significant Reduced Lvef or High Risk of Anthracycline Induced Cardiotoxicity
2022 · K. Lorenz, T. Strüßmann, et al. · HemaSphere · 1
Supplemental Material for: High-dose busulfan and thiotepa followed by autologous stem cell transplantation for refractory choriocarcinoma with central nervous system metastases: A case report
2026 · figshare admin karger, Julian Rapp, et al. · Figshare
Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapy
2026 · Tino Vollmer, Tim Strüßmann, et al. · Annals of Hematology
PDF
Works count: 32
Citation count: 238
H-index: 9
I10-index: 8
Year
Topic
Type